2024
KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Perry J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelson T, Owen S, Mason W, Drappatz J, Blondin N, de Groot J. KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology 2024, 26: v5-v5. PMCID: PMC11485821, DOI: 10.1093/neuonc/noae144.013.Peer-Reviewed Original Research500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Weller M, Berry D, Blondin N, Buxton M, Colman H, de Groot J, de la Fuente M, Ducray F, Ellingson B, Gordon G, Lassman A, Lee E, Lim M, Mellinghoff I, Perry J, Sulman E, Yung W, Wen P, Wick A, Cloughesy T. 500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Annals Of Oncology 2024, 35: s426-s427. DOI: 10.1016/j.annonc.2024.08.569.Peer-Reviewed Original ResearchBSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE
Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.Peer-Reviewed Original ResearchNon-small cell lung cancerLeptomeningeal diseaseCentral nervous systemLeptomeningeal metastasesParenchymal metastasesCerebrospinal fluidTumor cellsTyrosine kinase inhibitor treatmentCell lung cancerKinase inhibitor treatmentCerebrospinal fluid of patientsCell linesCerebral lateral ventriclesIntra-arterial injectionTGF-b signalingIn vivo passageIntraparenchymal diseaseMechanisms of progressionTumor microenvironmentMultiplex immunofluorescenceAggressive treatmentLeptomeningeal infiltrationPerivascular invasionIntraparenchymal metastasesMurine modelReal-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.
Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.Peer-Reviewed Original ResearchNon-small cell lung cancerDiagnosis of LMNational Comprehensive Cancer NetworkLeptomeningeal metastasesTumor cell assayPositive CTCsCerebrospinal fluidData cutoffOverall survivalNeurological symptomsAssessment of circulating tumor DNASensitivity of tumor cell detectionCTC assayManagement of leptomeningeal metastasisTime of data cutoffDiagnosis of leptomeningeal metastasisAssociated with longer survivalMedian overall survivalOmmaya reservoir placementEnumeration of circulating tumor cellsNegative cytology resultsCell lung cancerEffective treatment optionProgressive neurological symptomsInitiation of treatmentEvaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
de Groot J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelsen T, Owen S, Mason W, Drappatz J, Blondin N, Perry J. Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Journal Of Clinical Oncology 2024, 42: 2005-2005. DOI: 10.1200/jco.2024.42.16_suppl.2005.Peer-Reviewed Original ResearchOverall survivalHazard ratioBayesian predictive powerRandomized to CStage 1OS hazard ratioPromoter methylation statusSample sizeRecurrent glioblastomaIncreased OSEfficacy goalsInter-strand DNA crosslinksTargeted agentsRegistration trialsMultiple therapiesDNA double-strand breaksSubtypesDNA-targeting agentsPatient subtypesDouble-strand breaksGlioblastoma subtypesMethylation statusNDMRD
2023
SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Sweed N, Dugan M, Kesari S. SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY. Neuro-Oncology Advances 2023, 5: iii20-iii20. PMCID: PMC10402348, DOI: 10.1093/noajnl/vdad070.077.Peer-Reviewed Original ResearchNon-small cell lung cancerUpper GI cancerHER2-negative primary tumorsAnti-HER2 therapyBreast cancer patientsLeptomeningeal metastasesNegative primary tumorsPrimary tumorHER2 amplificationGI cancersCancer patientsNSCLC patientsBreast cancerHER2-positive primary tumorsUpper GI cancer patientsCSF tumor cellsGI cancer patientsPositive primary tumorsCell lung cancerDiscretion of physiciansIT trastuzumabLM tumorsHER2 positivityNSCLC cancerLM patientsAn expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroupThe clinical and genomic features of seizures in meningiomas
Dincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.Peer-Reviewed Original ResearchPeritumoral brain edemaPostoperative seizuresBrain invasionSubtotal resectionBrain edemaLarge residual tumor volumeCentral nervous system tumorsCommon central nervous system tumorPersistent postoperative seizuresResidual tumor volumeHistory of seizuresHigh tumor gradeNervous system tumorsQuality of lifePreoperative seizuresAtypical histologyMost patientsSurgical resectionCortical hyperexcitabilityUncontrolled seizuresAggressive featuresSeizure activityEpileptogenic focusCortical irritationRisk factorsImaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
2022
BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS
Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS. Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.Peer-Reviewed Original ResearchNon-small cell lung cancerUpper GI cancerLeptomeningeal metastasesHER2 amplificationPrimary tumorBreast cancerLM patientsGI cancersCancer patientsHER2-positive primary breast cancerHER2-positive primary tumorsSolid-tumor leptomeningeal metastasisUpper GI cancer patientsCSF tumor cellsGI cancer patientsPositive primary tumorsPrimary breast cancerBreast cancer patientsCell lung cancerIT trastuzumabLM tumorsNSCL cancerNSCLC patientsUpper GIClinical benefitTRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis
Jin L, Vetsa S, Vasandani S, Nadar A, Youngblood M, Gupte T, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Gorelick E, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, Marianayagam N, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis. Journal Of Neurological Surgery Part B Skull Base 2022, 83: s1-s270. DOI: 10.1055/s-0042-1743640.Peer-Reviewed Original Research
2021
BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER
Kumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.Peer-Reviewed Original ResearchCSF tumor cellsLeptomeningeal diseaseBreast cancer patientsIntrathecal treatmentTumor cellsCase seriesOmmaya reservoirCancer patientsCerebrospinal fluidLarge prospective clinical trialsSmilow Cancer HospitalYale-New HavenMetastatic breast cancerProspective clinical trialsBarrow Neurological InstituteIntrathecal therapyTumor cell detectionFourth patientCancer HospitalTumor InstituteClinical managementClinical trialsBreast cancerTreatment responsePatientsINNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER
Stuhlmiller T, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner M, Friedland J, Musella A, Blondin N, Fonkem E, Wong E, Kesari S. INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER. Neuro-Oncology 2021, 23: vi113-vi113. DOI: 10.1093/neuonc/noab196.448.Peer-Reviewed Original ResearchData elementsIndividual data elementsClinical decision support algorithmDecision support algorithmData solutionsBiomedical ontologiesMedical documentsLearning platformSupport algorithmData entryVirtual tumor boardsPlatformAlgorithmOntologyCase studyInfrastructureNon-profit groupsBrain tumor researchDocumentsClinical researchersDatabaseAccessReal-world evidenceResearchProtocolQOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS
Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.Peer-Reviewed Original ResearchMalignant glioma patientsMedical marijuana programMalignant gliomasInactive patientsCannabis therapyActive patientsComplementary therapiesGlioma patientsOil supplementsCannabis productsMedian overall survivalSignificant palliative benefitSerious adverse eventsOverall survivalAdverse eventsDaily groupPalliative benefitCannabis treatmentPatientsPatient registration processOil groupTherapyGliomasMonthsSurvivalNIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS
Jin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.Peer-Reviewed Original ResearchSphenoid wing meningiomaSpheno-orbital meningiomasBony involvementTRAF7 mutationsTumor invasionGenomic subgroupsPre-operative clinical featuresYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionLogistic regression modelsWhole-exome sequencingClinical featuresClinical variablesGrade IIPredictive logistic regression modelRecurrence patternsMolecular subtypesClinical implicationsExome sequencingHyperostosisMeningiomasTumorsGenomic driversINNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA
Blondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.Peer-Reviewed Original ResearchYear old womanStable diseaseAnaplastic oligodendrogliomaOlder womenCycles of temozolomideRecurrent anaplastic oligodendrogliomaRecurrent glioblastoma patientsTemporal lobe gliosarcomaTreatment of gliosarcomaGlioma subtypesImproved survival outcomesSmall case seriesStandard of careRight frontal lobeConventional radiation therapyConcurrent temozolomideFurther chemotherapyRadiographic progressionOverall survivalCase seriesInitial diagnosisRadiographic findingsSurvival outcomesSignificant thrombocytopeniaHistorical controlsSurgical strategies for older patients with glioblastoma
Barak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J. Surgical strategies for older patients with glioblastoma. Journal Of Neuro-Oncology 2021, 155: 255-264. PMID: 34626296, PMCID: PMC8651607, DOI: 10.1007/s11060-021-03862-z.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreLength of surgeryOlder patientsOverall survivalPostoperative complicationsSurgical resectionSurgical strategyLow preoperative KPS scorePoor Karnofsky performance scoreLow Karnofsky performance scoreYale-New Haven HospitalPostoperative adjuvant treatmentPreoperative KPS scoreAdjuvant treatment regimensExtent of resectionNew Haven HospitalUse of ioMRIAdjuvant treatmentHospital stayKPS scoreMethodsClinical dataConsecutive patientsPrognostic factorsTreatment regimensExperienced handsType of bony involvement predicts genomic subgroup in sphenoid wing meningiomas
Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal Of Neuro-Oncology 2021, 154: 237-246. PMID: 34350560, DOI: 10.1007/s11060-021-03819-2.Peer-Reviewed Original ResearchConceptsSpheno-orbital meningiomasSphenoid wing meningiomaBony involvementTRAF7 mutationsGenomic subgroupsPre-operative clinical featuresTumor invasionYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionWhole-exome sequencingBone involvementBone invasionClinical featuresClinical variablesGrade IIMolecular subtypesRecurrence patternsClinical implicationsHyperostosisExome sequencingMeningiomasTumorsGenomic driversHypermutated phenotype in gliosarcoma of the spinal cord
Hong CS, Kuzmik GA, Kundishora AJ, Elsamadicy AA, Koo AB, McGuone D, Blondin NA, DiLuna ML, Erson-Omay EZ. Hypermutated phenotype in gliosarcoma of the spinal cord. Npj Precision Oncology 2021, 5: 8. PMID: 33580181, PMCID: PMC7881101, DOI: 10.1038/s41698-021-00143-w.Peer-Reviewed Original ResearchSpinal cordWhole-exome sequencingLow-grade brain gliomasVariant of glioblastomaLow-grade gliomasTumor anteriorAdjuvant radiationNeurological deficitsSomatic single nucleotide variationsPoor prognosisGrade gliomasTemozolomide treatmentBrain gliomasGliosarcomaMicrosatellite stabilityCordSomatic mutationsHypermutator phenotypeGliomasComprehensive genetic characterizationGenomic mechanismsSingle nucleotide variationsPhenotypeFirst reportPathway genes
2020
Clinical and genomic factors associated with seizures in meningiomas.
Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.Peer-Reviewed Original ResearchPreoperative seizuresPostoperative seizuresAtypical histologyMultivariate analysisWorse progression-free survivalGenomic subgroupsYale-New Haven HospitalAssociation of seizuresAntiepileptic drug useProgression-free survivalSeizure-free patientsGross total resectionExtent of resectionMultiple risk factorsNF2 mutationsNew Haven HospitalLogistic regression modelsPostoperative radiationSeizure freedomClinical courseSeizure presentationSomatic NF2 mutationsBrain invasionRecurrent tumorsRisk factors